Stanford MoTrPAC Site for Genomes, Epigenomes and Transcriptomes
Project Number2U24DK112348-07
Former Number5U24DK112348-06
Contact PI/Project LeaderSNYDER, MICHAEL P. Other PIs
Awardee OrganizationSTANFORD UNIVERSITY
Description
Abstract Text
PROJECT SUMMARY
Lack of physical activity is central to numerous health problems. Despite this, we have limited understanding of
the molecular components which confer the benefit of physical activity and their diverse impacts across tissues
with respect to age, sex, genetics, environment and other objective physiologic, morphometric, and metabolic
measures. Identifying these molecular signatures offers new opportunities for treatment and therapeutics. The
goal of the Molecular Transducers of Physical Activity in Humans Consortium (MoTrPAC) is to assemble a
comprehensive map of the molecular changes that occur in response to physical activity and, when possible,
relate these changes to the benefits of physical activity. This map will be greatly facilitated by the application of
–omics technologies to identify exercise-responsive genes and to relate their benefits across multiple tissues
and contexts. Our Stanford Chemical Analysis Site (CAS) is a core component of the MoTrPAC project.
Together with Mount Sinai School of Medicine, we form the Genome, Epigenomics and Transcriptomics (GET)
team. At Stanford CAS, we have provided molecular data on 7820 samples as part of both human and rat
components of MoTrPAC studies. We have further led the development of key quality control and data analysis
pipelines to ensure rigor and reproducibility. Our site has also led key consortium manuscripts and
engagement efforts from the animal training study. In the final phase of MoTrPAC, we principally aim to provide
a genome for every MoTrPAC participant and a transcriptome for every participant sample and facilitate
making this data broadly accessible and useful to the research community. Our site will be responsible for the
generation of 15784 transcriptomes using RNA-seq. In addition to this effort, we have proposed to generate
chromatin accessibility profiles using ATAC-seq on 1190 muscle and PBMC samples and long read
transcriptomes using Iso-Seq on 110 muscle samples. The expected benefits of ATAC-seq and Iso-seq efforts
will be to enable (1) mapping regulatory changes using chromatin accessibility data, (2) expand profiling of
genetic effects using allele-specific measurements and (3) provide complete isoform data for a reference
collection of MoTrPAC samples through exercise intervention. Our site provides critical prior expertise and
infrastructure to accomplish these production goals and analyses. We have demonstrated expertise for
analysis of collected tissues, compliance with MoTrPAC protocols, collaboration with other Chemical Analysis
Sites and all other aspects of the consortium, timely data deposition and support of the Bioinformatics Center
and expertise in data sharing, enhancement of rigor and reproducibility in Common Fund projects and leading
coordinated publication activities. Our PI team also provides MoTrPAC with important cross-consortia expertise
to extend its impacts and ensure timely completion. Overall, we are eager to complete the MoTrPAC program
as envisioned, overcome remaining obstacles and rapidly share data, tools and analyses to the larger research
community.
Public Health Relevance Statement
NARRATIVE
While there are many important health benefits of physical activity, how exercise exerts its effects is not fully
understood. A more comprehensive understanding of the molecular mechanisms underlying the responses to
exercise would significantly impact public health. Continuation of the Molecular Transducers of Physical
Activity Consortium (MoTrPAC) will achieve its objective of generating a comprehensive map of the molecular
responses to acute exercise and exercise training. with a long-range goal of elucidating the mechanisms by
which exercise improves health.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
310
DUNS Number
009214214
UEI
HJD6G4D6TJY5
Project Start Date
13-December-2016
Project End Date
31-May-2027
Budget Start Date
08-August-2024
Budget End Date
31-May-2025
Project Funding Information for 2024
Total Funding
$885,999
Direct Costs
$573,834
Indirect Costs
$312,165
Year
Funding IC
FY Total Cost by IC
2024
NIH Office of the Director
$885,999
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 2U24DK112348-07
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2U24DK112348-07
Patents
No Patents information available for 2U24DK112348-07
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2U24DK112348-07
Clinical Studies
No Clinical Studies information available for 2U24DK112348-07
News and More
Related News Releases
No news release information available for 2U24DK112348-07
History
No Historical information available for 2U24DK112348-07
Similar Projects
No Similar Projects information available for 2U24DK112348-07